RELATED CONTENT
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to acquire Cianna Medical Inc., headquartered in Aliso Viejo, Calif. The deal structure includes an upfront payment of $135 million with potential earn-out payments of an additional $15 million for achievement of supply chain and scalability metrics, and up to an additional $50 million for achievement of sales milestones.
November 14, 2018 
Cianna Medical Inc. announced the company has received an additional U.S. Food and Drug Administration (FDA) 510(k) clearance for the Savi Scout radar localization system, allowing the reflector to be placed at the lumpectomy site up to 30 days prior to surgical removal.
August 17, 2016 
Cianna Medical Inc. recently announced receipt of the 2016 Scientific Impact Award at the Society of Breast Surgeons (ASBrS) Annual Meeting for data presented validating the clinical utility of Savi Scout breast localization and surgical guidance system.
May 19, 2016 Cianna Medical Inc. announced new clinical data evaluating the Savi Scout breast localization and surgical guidance system.
April 20, 2016 
Cianna Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for the SAVI Scout surgical guidance system. The technology uses real-time audible and visual indicators to give surgeons a precise way to target tissue during lumpectomy and excisional biopsy procedures.
December 16, 2014 
Cianna Medical Inc. announced five-year results for the first 200 hundred patients treated with the SAVI breast brachytherapy applicator, including excellent local control, low rates of toxicities and excellent cosmetic results.
September 17, 2014 
Cianna Medical Inc., a women’s health company announced the release of long-term data supporting the efficacy and safety of breast brachytherapy with the SAVI applicator.
September 08, 2014 
Today, only 12 percent of breast cancers in the United States are treated with accelerated partial breast irradiation (APBI). Breast brachytherapy is a form of APBI that delivers radiation dose from within the breast and tumor cavity using a tiny radioactive pellet of iridium-192. The clinical benefits of this targeted approach to radiation delivery are clear — reduced radiation exposure to healthy tissue, better cosmetic results and fewer side effects, and allowing more future treatment options in the event of a recurrence or new primary cancer.
June 03, 2014 
May 8, 2014 — Cianna Medical announced the results of a trial examining the long-term side effects of strut-based brachytherapy for early-stage breast cancer. According to researchers, treatment with SAVI breast brachytherapy resulted in very low rates of late toxicities, even in patients with minimal space between the tumor cavity and skin.
May 08, 2014 
April 7, 2014 — Cianna Medical announced the results of a retrospective study of breast cancer patients with ductal carcinoma in situ (DCIS) treated with SAVI breast brachytherapy. Researchers reported excellent local control, with recurrence rates that appear to be equivalent to those expected for whole breast irradiation (WBI) with similar follow-up.
April 07, 2014